Cytomegalovirus in transplantation - challenging the status quo. (Q36787493)

16 August 2017

1 reference

title

Cytomegalovirus in transplantation - challenging the status quo. (English)

1 reference

16 August 2017

0 references

Dino Sgarabotto

7

0 references

Vincent C Emery

object named as

Vincent Emery

2

0 references

Lionel Rostaing

5

object named as

Lionel Rostaing

1 reference

16 August 2017

Jay A Fishman

1

1 reference

16 August 2017

Richard Freeman

3

1 reference

16 August 2017

Manuel Pascual

4

1 reference

16 August 2017

Hans J Schlitt

6

1 reference

16 August 2017

Julian Torre-Cisneros

8

1 reference

16 August 2017

Marc E Uknis

9

1 reference

16 August 2017

1 March 2007

1 reference

16 August 2017

Clinical Transplantation

1 reference

16 August 2017

21

1 reference

16 August 2017

2

1 reference

16 August 2017

149-158

1 reference

Infection in organ-transplant recipients

16 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Investigation of CMV disease in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

The dynamics of human cytomegalovirus replication in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cytomegalovirus infection in simultaneous pancreas-kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

The role of viruses in cardiac allograft vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Impact of cytomegalovirus prophylaxis on rejection following orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Dynamics of Cytomegalovirus Replication during Preemptive Therapy with Oral Ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

The impact of early cytomegalovirus infection and disease in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin, and interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2006.00618.X

10.1111/J.1399-0012.2006.00618.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference